{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T03:14:41Z","timestamp":1794453281632,"version":"4.9.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T00:00:00Z","timestamp":1619740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013671","name":"Sun Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013671","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.ajo.2021.04.023","type":"journal-article","created":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T10:22:16Z","timestamp":1619864536000},"page":"60-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Clinically Relevant Activity of the Novel RASP Inhibitor Reproxalap in Allergic Conjunctivitis: The Phase 3 ALLEVIATE Trial"],"prefix":"10.1016","volume":"230","author":[{"given":"David","family":"Clark","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bill","family":"Cavanagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan L.","family":"Shields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Karpecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Sheppard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3399-4673","authenticated-orcid":false,"given":"Todd C.","family":"Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ajo.2021.04.023_bib0001","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jaci.2010.06.050","article-title":"The epidemiology of ocular and nasal allergy in the United States, 1988-1994","volume":"126","author":"Singh","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.ajo.2021.04.023_bib0002","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/112067211002000201","article-title":"Allergic conjunctivitis: a national cross-sectional study of clinical characteristics and quality of life","volume":"20","author":"Palmares","year":"2010","journal-title":"Eur J Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2021.04.023_bib0003","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1111\/cea.12536","article-title":"Allergic conjunctivitis: a cross-sectional study","volume":"45","author":"Leonardi","year":"2015","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"10.1016\/j.ajo.2021.04.023_bib0004","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/00002018-200225010-00004","article-title":"Locally administered ocular corticosteroids: benefits and risks","volume":"25","author":"McGhee","year":"2002","journal-title":"Drug Saf"},{"issue":"1","key":"10.1016\/j.ajo.2021.04.023_bib0005","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/2040622315612745","article-title":"Ocular itch associated with allergic conjunctivitis: latest evidence and clinical management","volume":"7","author":"Ackerman","year":"2016","journal-title":"Ther Adv Chronic Dis"},{"issue":"2","key":"10.1016\/j.ajo.2021.04.023_bib0006","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.alit.2016.08.011","article-title":"Evaluating the efficacy of epinastine ophthalmic solution using a conjunctivitis allergen challenge model in patients with birch pollen allergic conjunctivitis","volume":"66","author":"Tagawa","year":"2017","journal-title":"Allergol Int"},{"issue":"2","key":"10.1016\/j.ajo.2021.04.023_bib0007","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/BF02150945","article-title":"Tear histamine during allergic conjunctivitis challenge","volume":"223","author":"Kari","year":"1985","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2021.04.023_bib0008","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1089\/jop.2020.0056","article-title":"Randomized phase 2 trial of reproxalap, a novel reactive aldehyde species inhibitor, in patients with noninfectious anterior uveitis: model for corticosteroid replacement","volume":"36","author":"Mandell","year":"2020","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.ajo.2021.04.023_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2021.01.011","article-title":"Early onset and broad activity of reproxalap in a randomized, double-masked, vehicle-controlled phase 2b trial in dry eye disease","author":"Clark","year":"2021","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"10.1016\/j.ajo.2021.04.023_bib0010","article-title":"A randomized, multi-center, double-masked, vehicle-controlled, parallel-group phase 2b allergic conjunctivitis clinical trial of topical ocular ADX-102, a novel aldehyde sequestering agent","volume":"59","author":"Gomes","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10.1016\/j.ajo.2021.04.023_bib0011","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1042\/BJ20111752","article-title":"Cell signalling by reactive lipid species: new concepts and molecular mechanisms","volume":"442","author":"Higdon","year":"2012","journal-title":"Biochem J"},{"issue":"1-2","key":"10.1016\/j.ajo.2021.04.023_bib0012","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.imlet.2012.05.005","article-title":"Oxidative stress activates NLRP3 inflammasomes in ARPE-19 cells\u2013implications for age-related macular degeneration (AMD)","volume":"147","author":"Kauppinen","year":"2012","journal-title":"Immunol Lett"},{"issue":"1","key":"10.1016\/j.ajo.2021.04.023_bib0013","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.exer.2007.09.010","article-title":"Carotenoid derived aldehydes-induced oxidative stress causes apoptotic cell death in human retinal pigment epithelial cells","volume":"86","author":"Kalariya","year":"2008","journal-title":"Exp Eye Res"},{"issue":"1","key":"10.1016\/j.ajo.2021.04.023_bib0014","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12931-017-0517-x","article-title":"Malondialdehyde-acetaldehyde (MAA) adducted surfactant protein induced lung inflammation is mediated through scavenger receptor a (SR-A1)","volume":"18","author":"Sapkota","year":"2017","journal-title":"Respir Res"},{"issue":"4","key":"10.1016\/j.ajo.2021.04.023_bib0015","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s11882-002-0061-7","article-title":"The central role of conjunctival mast cells in the pathogenesis of ocular allergy","volume":"2","author":"Leonardi","year":"2002","journal-title":"Curr Allergy Asthma Rep"},{"issue":"1","key":"10.1016\/j.ajo.2021.04.023_bib0016","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1001\/archopht.1990.01070030090035","article-title":"Conjunctival allergen challenge. A clinical approach to studying allergic conjunctivitis","volume":"108","author":"Abelson","year":"1990","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2021.04.023_bib0017","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1586\/14737167.4.5.581","article-title":"The truly remarkable universality of half a standard deviation: confirmation through another look","volume":"4","author":"Norman","year":"2004","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.ajo.2021.04.023_bib0018","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.2147\/OPTH.S83263","article-title":"Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model","volume":"9","author":"Torkildsen","year":"2015","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2021.04.023_bib0019","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12916-016-0775-3","article-title":"Pain relief that matters to patients: systematic review of empirical studies assessing the minimum clinically important difference in acute pain","volume":"15","author":"Olsen","year":"2017","journal-title":"BMC Med"},{"issue":"3","key":"10.1016\/j.ajo.2021.04.023_bib0020","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3945\/ajcn.115.120378","article-title":"Best (but oft-forgotten) practices: expressing and interpreting associations and effect sizes in clinical outcome assessments","volume":"103","author":"McLeod","year":"2016","journal-title":"Am J Clin Nutr"},{"issue":"2","key":"10.1016\/j.ajo.2021.04.023_bib0021","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jclinepi.2007.03.012","article-title":"Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes","volume":"61","author":"Revicki","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ajo.2021.04.023_bib0022","unstructured":"US Food and Drug Administration. Patient-reported outcome measures: use in medical product development to support labeling claims. 2009; https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims. Accessed 8 January 2021."},{"key":"10.1016\/j.ajo.2021.04.023_bib0023","unstructured":"European Medicines Agency. Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man. 2016; https:\/\/www.ema.europa.eu\/en\/documents\/other\/appendix-2-guideline-evaluation-anticancer-medicinal-products-man_en.pdf. Accessed 8 January 2021."},{"issue":"11","key":"10.1016\/j.ajo.2021.04.023_bib0024","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1007\/BF00164671","article-title":"Oxidative reactions in the tear fluid of patients suffering from dry eyes","volume":"233","author":"Augustin","year":"1995","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"9","key":"10.1016\/j.ajo.2021.04.023_bib0025","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.3109\/02713683.2015.1098707","article-title":"Expression of lipid peroxidation markers in the tear film and ocular surface of patients with non-Sjogren syndrome: potential biomarkers for dry eye disease","volume":"41","author":"Choi","year":"2016","journal-title":"Curr Eye Res"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939421002221?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939421002221?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:44:00Z","timestamp":1762080240000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939421002221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":25,"alternative-id":["S0002939421002221"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2021.04.023","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinically Relevant Activity of the Novel RASP Inhibitor Reproxalap in Allergic Conjunctivitis: The Phase 3 ALLEVIATE Trial","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2021.04.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}